NCT02443324

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 175 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

Conditions

• Gastric Adenocarcinoma
• Adenocarcinoma of the Gastroesophageal Junction
• Non-small Cell Lung Cancer
• Carcinoma, Transitional Cell
• Biliary Tract Cancer

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV
DRUG	Pembrolizumab	Administered IV

Timeline

• Start date: 2015-07-29
• Primary completion: 2018-08-31
• Completion: 2022-04-12
• First posted: 2015-05-13
• Last updated: 2024-07-31
• Results posted: 2024-07-31

Locations

22 sites across 6 countries: United States, France, Germany, Japan, Spain, United Kingdom